Philip L Ballard
Overview
Explore the profile of Philip L Ballard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guardado M, Torgerson D, Chapin C, Atum A, Hernandez R, Clyman R, et al.
Am J Perinatol
. 2025 Jan;
PMID: 39788537
Objective: Extremely premature infants are treated with acetaminophen (APAP) for pain and patent ductus arteriosus. High doses of APAP in adults are toxic, and a recent study found an association...
2.
Ambalavanan N, Cotten C, Erickson S, Mathur R, Torgerson D, Ballard P
Am J Perinatol
. 2024 Jun;
42(2):238-249.
PMID: 38889886
Objective: Extremely preterm infants are at high risk of neonatal mortality and morbidity. Extreme preterm birth (PTB) may result from spontaneous preterm labor or preterm premature rupture of membranes or...
3.
Guardado M, Steurer M, Chapin C, Hernandez R, Ballard P, Torgerson D
Metabolites
. 2023 Sep;
13(9).
PMID: 37755251
Total Parenteral Nutrition (TPN), which uses intravenous administration of nutrients, minerals and vitamins, is essential for sustaining premature infants until they transition to enteral feeds, but there is limited information...
4.
Torgerson D, Guardado M, Steurer M, Chapin C, Hernandez R, Ballard P
Pediatr Res
. 2023 May;
94(4):1317-1326.
PMID: 37138028
Background: Extremely premature infants are at risk for circulatory collapse or respiratory failure that are often treated with hydrocortisone (HC); however, there is no information on the metabolic consequences of...
5.
Ballard P, Torgerson D, Wadhawan R, Hudak M, Weitkamp J, Harris J, et al.
Pediatr Res
. 2021 Jan;
90(4):784-794.
PMID: 33469180
Background: The pathogenesis of BPD includes inflammation and oxidative stress in the immature lung. Corticosteroids improve respiratory status and outcome, but the optimal treatment regimen for benefit with low systemic...
6.
Ballard P, Oses-Prieto J, Chapin C, Segal M, Ballard R, Burlingame A
PLoS One
. 2020 Dec;
15(12):e0243168.
PMID: 33301538
Background: Infants born at extremely low gestational age are at high risk for bronchopulmonary dysplasia and continuing lung disease. There are no early clinical biomarkers for pulmonary outcome and limited...
7.
Al Alam D, Ballard P, Jourdan Le Saux C, Ingram J, Mariani T, Moore N, et al.
Ann Am Thorac Soc
. 2020 Nov;
18(2):204-208.
PMID: 33252996
No abstract available.
8.
McEvoy C, Ballard P, Ward R, Rower J, Wadhawan R, Hudak M, et al.
Pediatr Res
. 2020 Feb;
88(4):629-636.
PMID: 32006953
Background: Initial trials of lung-targeted budesonide (0.25 mg/kg) in surfactant to prevent bronchopulmonary dysplasia (BPD) in premature infants have shown benefit; however, the optimal safe dose is unknown. Methods: Dose-escalation...
9.
Watterberg K, Ballard P
Pediatr Res
. 2019 Aug;
86(5):556-557.
PMID: 31412354
No abstract available.
10.
Rower J, Anderson D, Sherwin C, Reilly C, Ballard P, McEvoy C, et al.
J Pharm Biomed Anal
. 2019 Feb;
167:7-14.
PMID: 30738243
Budesonide is a potential therapeutic option for the prevention of bronchopulmonary dysplasia in mechanically ventilated premature neonates. The dose and concentrations of budesonide that drive effective prophylaxis are unknown, due...